Serum sFas and tumor tissue fasl negatively correlated with survival in egyptian patients suffering from breast ductal carcinoma

Pathology and Oncology Research

Volumn 15, Issue 2, 2009, Pages 241-250

  El Sarha, Ashgan I ^a   Magour, Gehan M ^a   Zaki, Sameh M ^a   El Sammak, Mohamed Y ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; DNA ploidy; FasL; S phase fraction; SFas

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; METHOTREXATE; NAVELBINE; TAMOXIFEN; DNA; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PLOIDY; PROGNOSIS; BLOOD; BREAST TUMOR; CANCER INVASION; ENZYME IMMUNOASSAY; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, CD95; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; PLOIDIES; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 68949133001     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9109-x     Document Type: Article

References (53)

1. JC Reed 2000 Mechanisms of apoptosis Am J Pathol 156 1415 1430
2. P Saas PR Walker M Hahne, et al. 1997 Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99 1173 1178 10.1172/JCI119273 1:CAS:528:DyaK2sXhvFyisb8%3D 9077524
3. P Schneioer JL Bodmer N Holler, et al. 1997 Characterization of Fas (Apo-1, CD95)-Fas ligand interaction J Biol Chem 272 18827 18833 10.1074/jbc.272.30.18827 (Pubitemid 27318231)
4. TS Griffith TA Ferguson 1997 The role of FasL induced apoptosis in immune privilege Immunol Today 18 2240 2244 10.1016/S0167-5699(97)81663-5 (Pubitemid 27219619)
5. M Müschen C Moers U Warskulat J Even D Niederacher MW Beckmann 2000 CD95 ligand expression as a mechanism of immune escape in breast cancer Immunology 99 1 69 77 10.1046/j.1365-2567.2000.00921.x 10651943 (Pubitemid 30062940)
6. SM Sheen-Chen HS Chen HL Eng WJ Chen 2003 Circulating soluble Fas in patients with breast cancer World J Surg 27 1 10 13 10.1007/s00268-002-6378-5 12557031 (Pubitemid 36920179)
7. T Suda T Takahashi P Golstein S Nagata 1993 Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family Cell 75 1169 1186 10.1016/0092-8674(93)90326-L 1:CAS:528:DyaK2cXhtlWrurY%3D 7505205 (Pubitemid 24006113)
8. MM Keane SA Ettenberg GA Lowrey EK Russell S Lipkowitz 1996 Fas expression and function in normal and malignant breast cell lines Cancer Res 56 4791 4798 1:CAS:528:DyaK28XmsV2itLw%3D 8841000
9. C Harrnring T Reimer U Jeschke J Makovitzky K Kruger B Gerber D Kabelitz K Friese 2000 Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors Histochem Cell Biol 113 189 194 10.1007/s004180050438
10. L Mullauer I Mosberger M Grusch M Rudas A Chott 2000 Fas ligand is expressed in normal breast epithelial cells and is frequently upregulated in breast cancer J Pathol 190 20 30 10.1002/(SICI)1096-9896(200001)190:1<20:: AID-PATH497>3.0.CO;2-S 1:CAS:528:DC%2BD3cXps1KltQ%3D%3D 10640988 (Pubitemid 30053349)
11. B Mann A Gratchev C Bohm, et al. 1999 FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas Br J Cancer 79 1262 1269 10.1038/sj.bjc.6690202 1:STN:280:DyaK1M7ps1Cjtw%3D%3D 10098769 (Pubitemid 29087908)
12. S Munakata T Enomoto M Tsujimoto, et al. 2000 Expression of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms Br J Cancer 82 1446 1452 1:CAS:528: DC%2BD3cXivFGisb0%3D 10780525
13. H Nagashima M Mori N Sadanaga, et al. 2001 Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis Int J Oncol 18 1157 1162 1:CAS:528:DC%2BD3MXktlCjsrc%3D 11351245
14. S Munakata O Watanabe K Ohashi H Morino 2005 Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance Am J Clin Pathol 123 6 879 885 10.1309/0773N4Q3GFP34J5V 1:CAS:528:DC%2BD2MXlsFSks78%3D 15899779
15. LS Gatierrez M Eliza T Niven-Fairchild F Naftolin G Mor 1999 The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas Breast Cancer Res Treat 54 3 245 253 10.1023/A:1006102601215 (Pubitemid 29322347)
16. I Robert 2002 New concepts for the study of anticancer drug resistance [French] Bull. Cancer 89 17 22 11847021
17. GN Hortobagyi 2001 Adjuvant systemic therapy for early breast cancer: progress and controversies Clin Cancer Res 7 1839 1842 1:STN:280: DC%2BD3MzpslehtQ%3D%3D 11448893
18. JS Ross GP Linette J Stec MS Ross S Anwar A Boguniewicz 2003 DNA ploidy and cell cycle analysis in breast cancer Am J Clin Pathol 120 Suppl S72 S84 15298145
19. EM Chávez-Uribe JE Viñuela J Cameselle-Teijeiro J Forteza JA Puñal IL Otero JL Puente-Dominguez 2002 DNA ploidy and cytonuclear area of peritumoral and paratumoral samples of mastectomy specimens: a useful prognostic marker? Eur J Surg 168 1 37 41 10.1080/110241502317307553 12022369 (Pubitemid 34293217)
20. A Chassevent ML Jourdan S Romain, et al. 2001 S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study Clin Cancer Res 7 4 909 917 1:CAS:528:DC%2BD3MXjs1elsLc%3D 11309341
21. Greene FL, Page DL, Fleming ID et al (2002) Breast IN: American joint committee on cancer, AJCC cancer staging manual, 6th edn. Springer, New York, p 171
22. Burtis CA, Ashwood ER, Bruns DE (2006) Teitz text book of clinical chemistry and molecular diagnostics, 4th edn. Elsevier Saunders, St Louis, pp 870-871, 797-803, 582-590, 546-549, 604-611, 1892-1904 & 1698
23. R Bouillon SW Coopman DEH Degroote PH Eliard 1990 Immunoradiometric assay of parathyrin polyclonal and monoclonal region specific antibodies Clin Chem 36 2 271 276 1:CAS:528:DyaK3cXhtlamsbk%3D 1689222
24. J Chen T Zhou C Liu JP Shapiro MJ Brauuer MC Kieler 1994 Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule Science 263 1759 1762 10.1126/science.7510905
25. Chamness GC, McGuire WL (1979) Methods for analyzing steroid receptors in human breast cancer. In: McGuire WL (ed) Breast cancer. Advances in research and treatment. Plenum, New York, p 149
26. M Bȩbenek D Duś J Koźlak 2006 Fas and Fas ligand as prognostic factors in human breast carcinoma Med Sci Monit 12 11 CR457 CR461 17072269
27. NM Almasri M Al Hamad 2005 Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan Breast Cancer Res 7 R598 R604 10.1186/bcr1200 1:CAS:528:DC%2BD2MXls1GitLk%3D 16168103
28. GE Feichter A Müller M Kaufmann, et al. 1988 Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer Int J Cancer 41 823 828 10.1002/ijc.2910410608 1:STN:280:DyaL1c3islSntQ%3D%3D 3372059
29. GE Feichter M Kaufmann A Müller, et al. 1989 DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases Breast Cancer Res Treat 13 17 22 10.1007/BF01806546 1:STN:280:DyaL1M3gslOntg%3D%3D 2706325
30. GG Konrey MD Pegram M Beryt, et al. 1999 Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cells with HER-2/neu overexpression Breast Cancer Res Treat 57 114
31. TJ Kev PK Verkasalo E Banks 2001 Epidemiology in breast cancer Lancet Oncol 2 3 133 140 10.1016/S1470-2045(00)00254-0 (Pubitemid 33585924)
32. GK Reeves V Beral J Green T Gathan D Bull 2006 Hormonal therapy of menopause and breast-cancer risk by histological type: a cohort study and meta-analysis Lancet Oncol 7 11 910 918 10.1016/S1470-2045(06)70911-1 1:CAS:528:DC%2BD28XhtFKmt7bN 17081916 (Pubitemid 44615945)
33. JJ Jager RL Jansen JW Arendo 2002 Clinical relevance of apoptotic markers in breast cancer is not yet clear Apoptosis 7 361 365 10.1023/A:1016179530785 1:CAS:528:DC%2BD38XltVSgtbY%3D 12101395 (Pubitemid 34832260)
34. L Zhang E Levi P Majumder Y Yu A Aboukameel J Du 2007 Transactivator of transcription-tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo Mol Cancer Ther 6 1661 1672 10.1158/1535-7163.MCT-06-0653 1:CAS:528:DC%2BD2sXotFaltbg%3D 17513614 (Pubitemid 46954033)
35. T Motyl B Gajkowska J Zarzy M Gajewska P Lamparska 2006 Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy J Physiol Pharmacol 7 17 32 (Pubitemid 46553587)
36. SM Sheen-Chen HS Chen HL Eng J Chenw 2003 Circulating soluble Fas in patients with breast cancer World J Surg 27 10 13 10.1007/s00268-002-6378-5 12557031 (Pubitemid 36920179)
37. M Djerbi Y Screpanti A Catrini, et al. 1999 The inhibitor of death receptor signaling. FLICE inhibitory protein defines a new class of tumor progression factors J Exp Med 190 1025 1031 10.1084/jem.190.7.1025 1:CAS:528:DyaK1MXmsVClt7Y%3D 10510092 (Pubitemid 29480831)
38. E Nemesansky K Tasnadi P Juhasz 1971 Diagnostic value of alkaline phosphatase isoenzyme in cancer patients Cancer 27 1388 1397 10.1002/1097-0142(197106)27:6<1388::AID-CNCR2820270619>3.0.CO;2-0
39. P Kao GG Cmklee R Taylor H Heath 1990 Parathyroid hormone related peptide in plasma of patients with hypercalcaemia and malignant lesions Mayo Clin Proc 65 1399 1407 1:CAS:528:DyaK3MXltFWksbs%3D 1700240
40. R Koomagi M Volm 1999 Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance Int J Cancer 84 239 243 10.1002/(SICI)1097-0215(19990621)84:3<239::AID-IJC7>3.0.CO;2-S 1:CAS:528:DyaK1MXkt1altrY%3D 10371340 (Pubitemid 29256748)
41. M Nagao Y Nakajima M Hisanaga, et al. 1999 The alteration of Fas receptor and ligand system in hepatocellular carcinoma: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30 413 421 10.1002/hep.510300237 1:CAS:528:DyaK1MXlt1ajsrY%3D 10421649 (Pubitemid 29357506)
42. M Shibakita M Tachibana DK Dahr, et al. 1999 Prognostic significance of Fas and Fas ligand expression in human esophageal cancer Clin Cancer Res 5 2464 2469 1:STN:280:DyaK1Mvisl2ltA%3D%3D 10499620 (Pubitemid 29437329)
43. S Ohno M Tachibana M Shibakita, et al. 2000 Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer Ann Surg Oncol 7 750 757 10.1007/s10434-000-0750-1 1:STN:280:DC%2BD3M7gsV2ntA%3D%3D 11129423
44. M Mottolese S Buglioni C Bracalenti, et al. 2000 Prognostic relevance of altered Fas (CD95)-system in human breast cancer Int J Cancer 89 127 132 10.1002/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO;2-4 1:CAS:528:DC%2BD3cXislehsrs%3D 10754489
45. M Bebenek D Duś J Koźlak 2007 Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread Anticancer Res 27 1A 215 218 1:CAS:528:DC%2BD2sXjs1WnsL4%3D 17352235
46. J Sjöström C Blomqvist K Boguslawski, et al. 2002 The predictive value of bcl-2, bcl-xL, bag-1, Fas, and FasL for chemotherapy response in advanced breast cancer Clin Cancer Res 8 811 816 11895913
47. TE Kute Y Quadri H Muss, et al. 1995 Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869 Cytometry 22 297 306 10.1002/cyto.990220406 1:STN:280:DyaK28zls1ertQ%3D%3D 8749780 (Pubitemid 26049992)
48. J Bryant B Fisher N Gunduz, et al. 1998 S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor positive breast cancer Breast Cancer Res Treat 51 239 253 10.1023/A:1006184428857 1:STN:280:DyaK1M7msFCmsw%3D%3D 10068082 (Pubitemid 29054557)
49. S Toikkanen L Pylkkanen H Joensuu 1997 Invasive lobular carcinoma of the breast has better short- and long-term survival then invasive ductal carcinoma Br J Cancer 76 1234 1240 1:STN:280:DyaK1c%2FjtVCmug%3D%3D 9365176
50. Y Remvikos H Magdelenat B Dutrillaux 1995 Genetic evolution of breast cancers. III. Age-dependent variations in the correlations between biological indicators of prognosis Breast Cancer Res Treat 34 25 33 10.1007/BF00666488 1:STN:280:DyaK2M3mvVWjug%3D%3D 7749157
51. E Leonardi A Cristofori O Caffo P Dalla Palma 1997 Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of P53 product in the different ploidy classes Anal Cell Pathol 15 31 45 1:STN:280:DyaK1c%2FktFSntw%3D%3D 9373711
52. P Dettmar N Harbeck C Thomssen, et al. 1997 Prognostic impact of proliferation-associated factors MIB1 (Ki67) and s-phase fraction in node-negative breast cancer Br J Cancer 75 1525 1533 1:STN:280: DyaK2szgvFGgtg%3D%3D 9166949
53. P Rudolph P Alm H Heidebrech, et al. 1999 Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer Natl Cancer Inst (Bethesda) 91 271 278 10.1093/jnci/91.3.271 1:STN:280: DyaK1M7lsVOisg%3D%3D